AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8077174 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment (sustained-release form, once a day at night, optimum dosage with plasma level of 0.5-0.79 mmol/L 12 hours after the nightly dose)
Number of subjects: 103
Study 8077174 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment (lower dosage after 1982)
Number of subjects: 103
Study 8077174 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 103
Study 2511685 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal NTG (1-3 mg t.i.d., five hourly with an eight-h washout period)
Number of subjects: 43
Study 2511685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 830201 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time, two-dimensional echocardiography
Number of subjects: 105
Study 830201 — intervention group
Group type: COMPARATOR
Intervention: Biplane cineangiography
Number of subjects: 105
Study 30640637 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirroring group (parents watching VR tour through mirroring display)
Number of subjects: 80
Study 30640637 — intervention group
Group type: COMPARATOR
Intervention: Control group (children watching VR tour via head mounted display)
Number of subjects: 80
Study 30640637 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirroring group
Number of subjects: 80
Study 30640637 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 26783978 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% hyaluronic acid (Visaid)
Number of subjects: 16
Study 26783978 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution
Number of subjects: 16
Study 25387438 — intervention group
Group type: EXPERIMENTAL
Intervention: Pocket-sized ultrasound
Number of subjects: 40
Study 25387438 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ultrasound)
Number of subjects: 40
Study 23870440 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive Classroom (RC) training
Number of subjects: 239
Study 23870440 — intervention group
Group type: COMPARATOR
Intervention: Control (business as usual)
Number of subjects: 239
Study 21986218 — intervention group
Group type: EXPERIMENTAL
Intervention: DSJI (Disposable-Syringe Jet Injector)
Number of subjects: 60
Study 21986218 — intervention group
Group type: COMPARATOR
Intervention: N-S (Needle-Syringe)
Number of subjects: 60
Study 21986218 — intervention group
Group type: EXPERIMENTAL
Intervention: DSJI
Number of subjects: 60
Study 21986218 — intervention group
Group type: COMPARATOR
Intervention: N-S
Number of subjects: 60
Study 17928803 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% (w/w) solution of galactose (Gal)
Number of subjects: 9
Study 17928803 — intervention group
Group type: COMPARATOR
Intervention: 8% solution of 50% galactose/50% glucose (Gluc/Gal)
Number of subjects: 9
Study 17928803 — intervention group
Group type: COMPARATOR
Intervention: 8% solution of 80% glucose/20% fructose (Gluc/Fru)
Number of subjects: 9
Study 17125431 — intervention group
Group type: EXPERIMENTAL
Intervention: B2000 needle-free device
Number of subjects: 27
Study 15592281 — intervention group
Group type: EXPERIMENTAL
Intervention: CTG, fetal scalp blood sampling, and continuous fetal pulse oximetry (study group)
Number of subjects: 146
Study 15592281 — intervention group
Group type: COMPARATOR
Intervention: CTG and fetal scalp blood sampling (control group)
Number of subjects: 146
Study 11304505 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum creatinine
Number of subjects: 2394
Study 11304505 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum uric acid
Number of subjects: 2394
Study 9282547 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervitec varnish
Number of subjects: 198
Study 9282547 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 198
Study 8512659 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 42-5892 (600 mg)
Number of subjects: 24
Study 8512659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3805544 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine (0.1 mg per nostril)
Number of subjects: 10
Study 3805544 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine (0.5 mg per nostril)
Number of subjects: 10
Study 3805544 — intervention group
Group type: COMPARATOR
Intervention: Histamine (5 mg per nostril)
Number of subjects: 10
Study 3805544 — intervention group
Group type: COMPARATOR
Intervention: Histamine (10 mg per nostril)
Number of subjects: 10
Study 3805544 — intervention group
Group type: COMPARATOR
Intervention: Saline (nebulized normal saline)
Number of subjects: 10
Study 31053954 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (weight-adjusted doses, titrated to maintenance dose)
Number of subjects: 60
Study 31053954 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 60
Study 31053954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28964657 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Simulator
Number of subjects: 36
Study 28964657 — intervention group
Group type: EXPERIMENTAL
Intervention: Box Trainer
Number of subjects: 36
Study 28964657 — intervention group
Group type: COMPARATOR
Intervention: Control (No Training)
Number of subjects: 36
Study 26168325 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect Consciousness (AC)
Number of subjects: 63
Study 24510471 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine 20 mg
Number of subjects: 0
Study 24510471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22840257 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal fluticasone furoate (FF)
Number of subjects: 26
Study 22840257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 21261107 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (5 mg once daily, n = 20)
Number of subjects: 54
Study 21261107 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine (1 mg once daily, n = 18)
Number of subjects: 54
Study 21261107 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg once daily, n = 16)
Number of subjects: 54
Study 21261107 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 23)
Number of subjects: 54
Study 21261107 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (n = 50)
Number of subjects: 54
Study 17919555 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray 110 microg QD for 2 weeks
Number of subjects: 53
Study 17919555 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray QD for 2 weeks
Number of subjects: 53
Study 17919555 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray
Number of subjects: 53
Study 17919555 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 53
Study 16246948 — intervention group
Group type: EXPERIMENTAL
Intervention: cilostazol 100 mg BID for 6 months
Number of subjects: 705
Study 16246948 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 705
Study 16246948 — intervention group
Group type: EXPERIMENTAL
Intervention: cilostazol
Number of subjects: 705
Study 14605480 — intervention group
Group type: EXPERIMENTAL
Intervention: ARNICA D12
Number of subjects: 60
Study 14605480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11243072 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified Verocell Rabies Vaccine (PVRV)
Number of subjects: 17
Study 11243072 — intervention group
Group type: COMPARATOR
Intervention: Non-pregnant women (control group)
Number of subjects: 17
Study 8888092 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam-clindamycin (A-C)
Number of subjects: 85
Study 8888092 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin-clindamycin (G-C)
Number of subjects: 85
Study 8888092 — intervention group
Group type: EXPERIMENTAL
Intervention: Infected patients
Number of subjects: 85
Study 8888092 — intervention group
Group type: COMPARATOR
Intervention: Noninfected patients
Number of subjects: 85
Study 1891675 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical vitamin A acid at 0.025% for 6 months followed by 0.05%
Number of subjects: 0
Study 6130243 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 30
Study 6130243 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (UCT)
Number of subjects: 30
Study 3720528 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (DZ) 80 mg every third day (3 subjects) or every sixth day (3 subjects) for a total of 3-6 dosing occasions
Number of subjects: 11
Study 3720528 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (TZ) 2.0 or 3.0 mg every second day (4 subjects) or every third day (2 subjects) for a total of 3-5 dosing occasions
Number of subjects: 11
Study 30382270 — intervention group
Group type: EXPERIMENTAL
Intervention: Strawberry supplementation (50 g day-1 for 12 weeks)
Number of subjects: 17
Study 30382270 — intervention group
Group type: COMPARATOR
Intervention: Placebo (50 g day-1, matched for calories and fiber)
Number of subjects: 17
Study 28853317 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mm then 4 mm drop shoes (EXP)
Number of subjects: 30
Study 28853317 — intervention group
Group type: COMPARATOR
Intervention: 12 mm drop shoes (CON)
Number of subjects: 30
Study 25684620 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL Evicel® (fibrin haemostatic sealant)
Number of subjects: 60
Study 25684620 — intervention group
Group type: COMPARATOR
Intervention: Untreated (control group)
Number of subjects: 60
Study 25684620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of treatment with Evicel®
Number of subjects: 60
Study 23391304 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app (on mobile phone or iPad)
Number of subjects: 35
Study 23391304 — intervention group
Group type: COMPARATOR
Intervention: Computer
Number of subjects: 35
Study 20578381 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (therapeutic principle of dredging meridians and collaterals, tonifying qi and eliminating blood stasis, supplementing liver and kidney, nourishing blood and tendon; points included Hegu (LI 4), Taichong (LR 3), Zusanli (ST 36), Qihai (CV 6), Quchi (LI 11))
Number of subjects: 64
Study 20578381 — intervention group
Group type: COMPARATOR
Intervention: Cobamamide (intramuscular injection)
Number of subjects: 64
Study 18227370 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 42418
Study 18227370 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 42418
Study 18227370 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 42418
Study 17016485 — intervention group
Group type: EXPERIMENTAL
Intervention: Level-III dissection (group-A, n=258)
Number of subjects: 514
Study 17016485 — intervention group
Group type: COMPARATOR
Intervention: Level-I dissection (group-B, n=256)
Number of subjects: 514
Study 17016485 — intervention group
Group type: EXPERIMENTAL
Intervention: Level-III dissection (group-A)
Number of subjects: 514
Study 17016485 — intervention group
Group type: COMPARATOR
Intervention: Level-I dissection (group-B)
Number of subjects: 514
Study 11952999 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA exposure
Number of subjects: 53
Study 11952999 — intervention group
Group type: COMPARATOR
Intervention: No UVA exposure (Control)
Number of subjects: 53
Study 9828757 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid-rich diet (n=15)
Number of subjects: 29
Study 9828757 — intervention group
Group type: COMPARATOR
Intervention: Linoleic acid-rich diet (n=14)
Number of subjects: 29
Study 7926539 — intervention group
Group type: EXPERIMENTAL
Intervention: One hypertonic phosphate enema 1 hour before fiberoptic flexible sigmoidoscopy
Number of subjects: 0
Study 7926539 — intervention group
Group type: EXPERIMENTAL
Intervention: Two hypertonic phosphate enemas 1 hour before fiberoptic flexible sigmoidoscopy
Number of subjects: 0
Study 7926539 — intervention group
Group type: EXPERIMENTAL
Intervention: One enema 3 hours before and a second enema 1 hour before fiberoptic flexible sigmoidoscopy
Number of subjects: 0
Study 7926539 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 0
Study 2510510 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3 prophylaxis (14 days post-transplant)
Number of subjects: 0
Study 2510510 — intervention group
Group type: COMPARATOR
Intervention: Triple-drug immunosuppressant therapy (cyclosporine, azathioprine, prednisone)
Number of subjects: 0
Study 2510510 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3 prophylaxis
Number of subjects: 0
Study 2510510 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3 prophylaxis with 2 g intravenous methylprednisolone
Number of subjects: 0
Study 776312 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenothiazine withdrawal
Number of subjects: 31
Study 776312 — intervention group
Group type: COMPARATOR
Intervention: Active medication (control group)
Number of subjects: 31
Study 30043569 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified clinical nursing protocol
Number of subjects: 120
Study 30043569 — intervention group
Group type: COMPARATOR
Intervention: Conventional epilepsy nursing protocol
Number of subjects: 120
Study 27594602 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoanalytic Therapy (PT)
Number of subjects: 200
Study 27594602 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 200
Study 24801367 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-protein, higher-haem iron diet (HPHI)
Number of subjects: 76
Study 24801367 — intervention group
Group type: COMPARATOR
Intervention: Lower-protein, lower-haem iron diet (LPLI)
Number of subjects: 76
Study 22390832 — intervention group
Group type: EXPERIMENTAL
Intervention: One-hour in vivo exposure treatment
Number of subjects: 32
Study 22390832 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 32
Study 20535921 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiantai No. 1 (TT1)
Number of subjects: 128
Study 20535921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 18717242 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled human insulin (Exubera)
Number of subjects: 121
Study 18717242 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin
Number of subjects: 121
Study 16448231 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrusion with continuous force of 100 cN for eight weeks
Number of subjects: 9
Study 16448231 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrusion with continuous force of 100 cN for eight weeks
Number of subjects: 9
Study 16448231 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 9
Study 14520165 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg once daily
Number of subjects: 32
Study 14520165 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg split dose
Number of subjects: 32
Study 14520165 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg once daily
Number of subjects: 32
Study 14520165 — intervention group
Group type: COMPARATOR
Intervention: Modafinil (all doses)
Number of subjects: 32
Study 10416152 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean children with Class III malocclusions
Number of subjects: 141
Study 10416152 — intervention group
Group type: COMPARATOR
Intervention: European-American children with Class III malocclusions
Number of subjects: 141
Study 10416152 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin-plate spline analysis
Number of subjects: 141
Study 10416152 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial warp (PW) 8
Number of subjects: 141
Study 10416152 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial warp (PW) 9, PW4, PW5
Number of subjects: 141
Study 7494611 — intervention group
Group type: EXPERIMENTAL
Intervention: Regenerated cellulose low‐flux membrane, followed by regenerated cellulose high‐flux membrane, and then polymethylmethacrylate (PMMA) high‐flux membrane
Number of subjects: 18
Study 7494611 — intervention group
Group type: EXPERIMENTAL
Intervention: Regenerated low‐flux cellulose membrane, followed by PMMA low‐flux membrane and PMMA high‐flux membrane
Number of subjects: 18
Study 7494611 — intervention group
Group type: EXPERIMENTAL
Intervention: Same membrane throughout the 6‐week study period
Number of subjects: 18
Study 2098372 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide
Number of subjects: 40
Study 2098372 — intervention group
Group type: COMPARATOR
Intervention: Low-dose subcutaneous heparin (LDSH)
Number of subjects: 40
Study 552657 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol aerosol (400 micrograms)
Number of subjects: 59
Study 552657 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol aerosol (200 micrograms)
Number of subjects: 59
Study 30975019 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream denture adhesive
Number of subjects: 200
Study 30975019 — intervention group
Group type: EXPERIMENTAL
Intervention: Powder denture adhesive
Number of subjects: 200
Study 30975019 — intervention group
Group type: COMPARATOR
Intervention: Control (saline solution)
Number of subjects: 200
Study 30133938 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional training (FT) programme for 10 weeks
Number of subjects: 38
Study 30133938 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 38
Study 27591988 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical therapy
Number of subjects: 407
Study 27591988 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined topical and NB-UVB therapy
Number of subjects: 407
Study 27591988 — intervention group
Group type: COMPARATOR
Intervention: NB-UVB therapy
Number of subjects: 407
Study 25386609 — intervention group
Group type: EXPERIMENTAL
Intervention: Cynatine HNS (500 mg keratin plus vitamins and minerals)
Number of subjects: 50
Study 25386609 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 50
Study 22788983 — intervention group
Group type: EXPERIMENTAL
Intervention: Life-review therapy with computer supplements (6 weeks)
Number of subjects: 36
Study 22788983 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 36
Study 19851113 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual fibreoptic intubation (VFI) software, self-training until competency, evaluated 2 weeks later.
Number of subjects: 42
Study 19851113 — intervention group
Group type: COMPARATOR
Intervention: Control group taught conventionally by an expert bronchoscopist with a 1 h lecture.
Number of subjects: 42
Study 19851113 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 42
Study 19851113 — intervention group
Group type: EXPERIMENTAL
Intervention: VFI group (I)
Number of subjects: 42
Study 17607121 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (110 mg/m2 on day 1), topotecan (1.5 mg/m2 on days 2-4), etoposide (160 mg/m2 on days 5-7 every 21 days) followed by chest irradiation to 70 Gy and carboplatin (AUC 5 on day 1) and etoposide (100 mg/m2 on days 1-3 every 21 days) without filgrastim for three cycles.
Number of subjects: 65
Study 15983290 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (2.5 to 10 mg/d)
Number of subjects: 31512
Study 15983290 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (10 to 40 mg/d)
Number of subjects: 31512
Study 15983290 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone (12.5 to 25 mg/d)
Number of subjects: 31512
Study 12270981 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg twice daily, n=11)
Number of subjects: 21
Study 12270981 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=10)
Number of subjects: 21
Study 12270981 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (100 mg/kg/30 min)
Number of subjects: 21
Study 12270981 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (500 mg/kg/30 min)
Number of subjects: 21
Study 12270981 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including hypercholesterolaemic patients, young healthy, and older healthy controls)
Number of subjects: 21
Study 10097934 — intervention group
Group type: EXPERIMENTAL
Intervention: nisoldipine (20-40 mg/day)
Number of subjects: 50
Study 10097934 — intervention group
Group type: COMPARATOR
Intervention: lisinopril (10-20 mg/day)
Number of subjects: 50
Study 8947977 — intervention group
Group type: COMPARATOR
Intervention: Caffeine with water
Number of subjects: 10
Study 8947977 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine with grapefruit juice (GFJ)
Number of subjects: 10
Study 8947977 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine with multiple GFJ doses
Number of subjects: 10
Study 8947977 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine with GFJ
Number of subjects: 10
Study 1755386 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing home care
Number of subjects: 0
Study 1755386 — intervention group
Group type: COMPARATOR
Intervention: Long-stay geriatric ward care
Number of subjects: 0
Study 7007357 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxapine
Number of subjects: 46
Study 7007357 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 46
Study 31615021 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher preconception vegetable intake (per 10 g/day)
Number of subjects: 46
Study 31615021 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher preconception fruit intake (per 10 g/day)
Number of subjects: 46
Study 31615021 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher preconception intake of sugary drinks
Number of subjects: 46
Study 28403943 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 (250,000 IU vitamin D3 bolus)
Number of subjects: 25
Study 28403943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 26289822 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency department physician diagnosis
Number of subjects: 477
Study 26289822 — intervention group
Group type: EXPERIMENTAL
Intervention: Disagreement between emergency department diagnosis and adjudication committee diagnosis
Number of subjects: 477
Study 26289822 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement between emergency department diagnosis and adjudication committee diagnosis
Number of subjects: 477